Abbott Laboratories (ABT) Stake Raised by Hall Laurie J Trustee

Hall Laurie J Trustee increased its stake in Abbott Laboratories (NYSE:ABT) by 3.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 68,526 shares of the healthcare product maker’s stock after buying an additional 2,210 shares during the quarter. Abbott Laboratories makes up 2.1% of Hall Laurie J Trustee’s holdings, making the stock its 13th biggest position. Hall Laurie J Trustee’s holdings in Abbott Laboratories were worth $3,331,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ABT. Vanguard Group Inc. lifted its holdings in Abbott Laboratories by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 129,786,955 shares of the healthcare product maker’s stock valued at $6,308,944,000 after purchasing an additional 3,241,063 shares during the last quarter. State Street Corp lifted its holdings in Abbott Laboratories by 18.9% during the 1st quarter. State Street Corp now owns 80,499,469 shares of the healthcare product maker’s stock valued at $3,574,987,000 after purchasing an additional 12,806,535 shares during the last quarter. Capital Research Global Investors lifted its holdings in Abbott Laboratories by 45.7% during the 2nd quarter. Capital Research Global Investors now owns 47,589,663 shares of the healthcare product maker’s stock valued at $2,313,334,000 after purchasing an additional 14,918,038 shares during the last quarter. Northern Trust Corp lifted its holdings in Abbott Laboratories by 3.1% during the 2nd quarter. Northern Trust Corp now owns 26,865,706 shares of the healthcare product maker’s stock valued at $1,305,942,000 after purchasing an additional 809,732 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Abbott Laboratories by 28.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 11,722,088 shares of the healthcare product maker’s stock valued at $569,830,000 after purchasing an additional 2,606,404 shares during the last quarter. 71.32% of the stock is owned by institutional investors.

In other Abbott Laboratories news, insider Daniel Gesua Sive Salvadori sold 28,319 shares of Abbott Laboratories stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $54.92, for a total value of $1,555,279.48. Following the transaction, the insider now owns 102,117 shares in the company, valued at $5,608,265.64. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jaime Contreras sold 52,700 shares of Abbott Laboratories stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $51.97, for a total value of $2,738,819.00. Following the completion of the transaction, the insider now owns 58,739 shares in the company, valued at approximately $3,052,665.83. The disclosure for this sale can be found here. Insiders sold 616,332 shares of company stock worth $33,579,226 in the last 90 days. 0.76% of the stock is owned by company insiders.

Abbott Laboratories (NYSE ABT) opened at $54.73 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. Abbott Laboratories has a 12-month low of $37.90 and a 12-month high of $56.69. The company has a market capitalization of $95,837.49, a price-to-earnings ratio of 22.85, a P/E/G ratio of 2.06 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The company had revenue of $6.83 billion for the quarter, compared to analysts’ expectations of $6.72 billion. During the same quarter last year, the business earned $0.59 earnings per share. Abbott Laboratories’s revenue was up 28.8% on a year-over-year basis. analysts expect that Abbott Laboratories will post 2.49 EPS for the current fiscal year.

Several equities research analysts have issued reports on ABT shares. Cowen reaffirmed a “buy” rating on shares of Abbott Laboratories in a report on Sunday, September 24th. Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a report on Friday, September 22nd. Bank of America reiterated a “buy” rating and set a $60.00 price objective (up previously from $56.00) on shares of Abbott Laboratories in a research report on Wednesday, October 4th. Royal Bank of Canada reiterated a “buy” rating and set a $55.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, October 3rd. Finally, Jefferies Group reiterated a “buy” rating and set a $65.00 price objective on shares of Abbott Laboratories in a research report on Thursday, October 19th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $57.56.

COPYRIGHT VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/15/abbott-laboratories-abt-stake-raised-by-hall-laurie-j-trustee.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply